The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Sagar Doshi of Nuvama Professional Clients Group recommends these three stocks today- Oil and Natural Gas Corporation Ltd ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

The report said "Nifty EPS is likely to grow 2 per cent (versus 4 per cent in H1FY25)-posing downgrade risks to H2FY25 consensus estimate of mid-teens growth".

Media companies are likely to report a subdued performance in the upcoming Q3FY25 results, according to a report by Nuvama.

Multi-Manager ICVC also sold 4.35 lakh shares or 0.52 percent stake in Dr Lal PathLabs at Rs 2,997.11 per share.

Nuvama, BofA, and Bernstein have provided positive outlooks for SBI Cards, Bajaj Finance, and HDFC Bank, respectively. Nuvama ...